LOS CABOS, BAJA CALIFORNIA SUR, Mexico, March 11, 2026 — Physicians and scientists from Longevity Medical Institute® have published new peer-reviewed research examining the therapeutic potential of allogeneic mesenchymal stem cell therapies for diabetic foot ulcers, one of the most serious and difficult-to-treat complications of diabetes. The publication adds to the growing body of evidence supporting stem cell-based approaches in chronic wound care and reflects Longevity Medical Institute’s broader investment in clinical research, diagnostics, and regenerative medicine infrastructure. [Read more…]
Types of CAR-T Cells: Improvements in CAR Design and Construction
What are the types of CAR-T cells and how have they changed in recent years? CAR-T cells are immune cells that are artificially engineered to express a particular chimeric antigen receptor (CAR), which have shown great potential in killing cancer cells. Chimeric antigen receptors (CARs) are artificially produced recombinant receptors having both antigen-binding and T-cell activating potentials.
CARs are composed of an extracellular recognition domain sourced from monoclonal antibodies (mAbs) and an intracellular signaling domain including CD3- and costimulatory domains for triggering endogenous signaling pathways of T-cells. [Read more…]
World-First EXO 001 Exosome Platform Enables In Vivo Multi-Target CAR-T for Solid Tumors
Jointly developed by China Medical University Hospital and Ever Supreme Bio Technology, the platform demonstrates compelling preclinical tumor clearance across multiple models
TAICHUNG, Feb. 13, 2026 — Cancer has long ranked among the leading causes of death in Taiwan, and solid tumors account for more than 90% of cancer cases worldwide—making them the most challenging frontier for CAR-T cell therapy. China Medical University Hospital (CMUH) announced today that, in collaboration with Ever Supreme Bio Technology, it has successfully developed the world’s first EXO 001 targeted exosome platform, a breakthrough technology that enables direct in vivo programming of T cells to generate multi-target nanobody-based CAR-T cells. [Read more…]
BREAKING: Gilead Sciences to Acquire Arcellx a Staggering $7.8 Billion CAR-T Cell Therapy Deal
Today, February 23rd, 2026, Gilead Sciences announced a definitive agreement to acquire Arcellx in a transaction valued at approximately $7.8 billion, providing Gilead with full ownership of anitocabtagene autoleucel (anito-cel), an investigational BCMA-directed CAR-T therapy for patients with relapsed or refractory multiple myeloma. Arcellx is a clinical-stage biotech company headquartered in Rockville, Maryland, founded in 2014. [Read more…]
The Pipeline for iPSC-Derived Cell Therapeutics in 2026
Despite progress involving the use of induced pluripotent stem cells (iPSCs) within disease modeling and drug discovery applications, it will be a long path to achieve the broad-scale use of iPSC-derived cell types in human patients. [Read more…]
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 62
- Next Page »